Journal
CELL REPORTS PHYSICAL SCIENCE
Volume 1, Issue 2, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.xcrp.2020.100014
Keywords
-
Categories
Funding
- NYU Abu Dhabi
- Al Jalila Foundation Research Center seed grant [AJF201624]
- NYU
- Stockholm University
Ask authors/readers for more resources
Amyloid proteins and peptides are a major contributing factor to the development of various neurodegenerative disorders, including Alzheimer's and prion diseases. Previously, a designed cell-penetrating peptide (CPP) comprising a hydrophobic signai sequence followed by a prion protein (PrP)-derived polycationic sequence (PrP23-28: KKRPKP) was shown to have potent anti-prion properties. Here, we extend this approach toward the amyloid-beta (A beta) peptide amyloid formation, which is associated with Alzheimer's disease. We characterized the interactions of the CPP with A beta using complementary in vitro and in silico experiments. We report that the CPP stabilizes A beta in a non-amyloid state and inhibits A beta-induced neurotoxicity. Moreover, replacing PrP23-28 with a corresponding segment from A beta results in a construct with similar CPP functionality and antagonism of A beta aggregation and neurotoxicity. Our findings reveal a general underlying principle for inhibition of pathogenic protein aggregation that may facilitate the design of CPP-based therapeutics for amyloid diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available